Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
40S ribosomal protein S26 (RPS26)
- Target
- RPS26
- Molecular classification
- Ribosomal protein (structural constituent of ribosome), Other (not an enzyme, receptor, ion channel, transporter, transcription factor, or histone modification)
01
Overview
40S ribosomal protein S26 (RPS26) is a highly conserved structural protein of the small (40S) ribosomal subunit in eukaryotes. It is critical for protein synthesis, acting as part of the ribosome’s apparatus for translating mRNA into polypeptides. RPS26 has distinct motifs mediating mRNA binding and influences ribosome assembly, especially during the final maturation of pre-40S subunits. Beyond its structural role, RPS26 is involved in regulating cell growth and division, and it participates in cellular stress responses through interactions with p53 signaling pathways. Mutations in the RPS26 gene are causally linked to Diamond–Blackfan anemia, a disorder of erythropoiesis with physical abnormalities. While not itself a conventional drug target, its gene status serves as a biomarker for disease diagnosis and molecular studies of ribosomopathies.
- Other names
- RPS2640S ribosomal protein S26DBA10S26ribosomal protein S26eS26Small ribosomal subunit protein eS26
02
Mechanism of action
null
03
Biological functions
Structural component of the small ribosomal subunit (40S)Protein synthesis (translation)Ribosome biogenesismRNA bindingAutoregulation via pre-mRNA splicingRegulation of cell cycle and apoptosis (via p53 signaling and DNA damage response)
04
Disease associations
Diamond–Blackfan anemia (DBA)Other: mutations may play a role in cellular stress responses and maintenance of genomic integrity
05
Safety considerations
Targeting ribosomal proteins risks broad interruption of protein synthesis, leading to cytotoxicity and cell death. Ribosome inhibition or dysfunction can trigger apoptosis and stress responses, with associated anemia and possible developmental defects as seen in human ribosomopathies
06
Interacting drugs
None established as direct binders or clinical modulators. There are no known drugs that specifically target RPS26 for therapeutic purposes; ribosomal proteins are generally not directly drugged
07
Biomarkers
RPS26 mutation status (can be used as a genetic biomarker for Diamond–Blackfan anemia risk and diagnosis)
Beyond the preview
Go deeper on 40S ribosomal protein S26 (RPS26).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 40S ribosomal protein S26 (RPS26).